Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

3 Months Ended

Sep. 30, 2021

Notes Tables

Schedule of Stockholders Equity [Table Text Block]

																		Accumulated
										Additional								Other
		Common Stock								Paid-in				Retained				Comprehensive				Non-Controlling
		Shares				Amount				Capital				Earnings				Income(Loss)				Interest				Total
Balances at June 30, 2021			38,955			$	390			$	534,411			$	1,085,461			$	(57,291	)		$	8,263			$	1,571,234
Net earnings															69,615								(634	)			68,981
Other comprehensive income																			(6,925	)			(39	)			(6,964	)
Common stock issued for exercise of options			295				3				36,345				(13,481	)											22,867
Common stock issued for restricted stock awards			20				0				0				(9,765	)											(9,765	)
Cash dividends															(12,493	)											(12,493	)
Stock-based compensation expense											11,396																11,396
Common stock issued to employee stock purchase plan			3				0				1,358																1,358
Employee stock purchase plan expense											341																341
Balances at September 30, 2021			39,273			$	393			$	583,851			$	1,119,337			$	(64,216	)		$	7,590			$	1,646,955

																		Accumulated
										Additional								Other
		Common Stock								Paid-in				Retained				Comprehensive
		Shares				Amount				Capital				Earnings				Income(Loss)				Total
Balances at June 30, 2020			38,453			$	385			$	420,536			$	1,057,470			$	(97,199	)		$	1,381,192
Cumulative effect adjustments due to adoption of new accounting standards and other															(276	)							(276	)
Net earnings															33,395								33,395
Other comprehensive loss																			14,057				14,057
Common stock issued for exercise of options			117				1				13,727												13,728
Common stock issued for restricted stock awards			25				0								(4,890	)							(4,890	)
Cash dividends															(12,336	)							(12,336	)
Stock-based compensation expense											12,667												12,667
Common stock issued to employee stock purchase plan			6				0				1,463												1,463
Employee stock purchase plan expense											286												286
Balances at September 30, 2020			38,601			$	386			$	448,679			$	1,073,362			$	(83,142	)		$	1,439,285

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

		Unrealized Gains (Losses) on Derivative Instruments				Foreign Currency Translation Adjustments				Total
Balance as of June 30, 2021		$	(6,193	)		$	(51,098	)		$	(57,291	)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne			84				(8,607	)			(8,523	)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽¹⁾			1,598				-				1,598
Balance as of September 30, 2021⁽²⁾		$	(4,511	)		$	(59,705	)		$	(64,216	)

		Unrealized Gains (Losses) on Derivative Instruments				Foreign Currency Translation Adjustments				Total
Balance as of June 30, 2020		$	(13,253	)		$	(83,946	)		$	(97,199	)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne			11				11,914				11,925
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne ⁽³⁾			2,132				-				2,132
Balance as of September 30, 2020⁽²⁾		$	(11,110	)		$	(72,032	)		$	(83,142	)